Cover Image
市場調查報告書

脊髓損傷:開發平台分析

Spinal Cord Injury - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229793
出版日期 內容資訊 英文 192 Pages
訂單完成後即時交付
價格
Back to Top
脊髓損傷:開發平台分析 Spinal Cord Injury - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 192 Pages
簡介

脊髓損傷的定義為脊髓受到肉體性外傷,常會留下喪失運動機能或感覺這樣的障礙。一般是由於身體受到外傷及疾病(橫斷性脊髓炎,小兒麻庳,脊椎破裂,遺傳性共濟失調症)所引起。若發生在意外事故後該疾病的緊急症狀有背部激烈的疼痛、頭部或頸部甚至背部感到壓迫感,身體某部位感到無力,失去知覺、手、指、足、腳尖失去知覺,無法控制膀胱及腸道,失去平衡感行走困難,事故後造成呼吸障礙,頸部及背產生奇妙的扭曲。

本報告提供脊髓損傷的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃相關資訊等,同時再加上最新的新聞和發表。

簡介

  • 調查範圍

脊髓損傷 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Acorda Therapeutics, Inc.
  • Asterias Biotherapeutics, Inc.
  • Asubio Pharma Co., Ltd.
  • Athersys, Inc.
  • BioArctic Neuroscience AB
  • BioAxone BioSciences, Inc.
  • FirstString Research, Inc.
  • Genervon Biopharmaceuticals, LLC
  • Histocell S.L.
  • Kadimastem Ltd. .
  • Kringle Pharma, Inc.
  • Lipopharma Therapeutics SL
  • Lpath, Inc.
  • MandalMed, Inc.
  • Mapreg S.A.S.
  • Neuralstem, Inc.
  • Neuronax SAS
  • New World Laboratories, Inc.
  • Omeros Corporation
  • PharmatrophiX, Inc.
  • Pharmicell Co., Ltd.
  • Protagenic Therapeutics Inc.
  • Q Therapeutics, Inc.
  • Remedy Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • RhinoCyte, Inc.
  • SanBio, Inc.
  • Sirnaomics, Inc.
  • StemCells, Inc.
  • Stemedica Cell Technologies, Inc.
  • TissueGene, Inc.
  • Tumorend, LLC
  • Vertex Pharmaceuticals Incorporated
  • Vicore Pharma AB

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8703IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2016, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 23 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.Spinal Cord Injury.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Spinal Cord Injury Overview
  • Therapeutics Development
    • Pipeline Products for Spinal Cord Injury - Overview
    • Pipeline Products for Spinal Cord Injury - Comparative Analysis
  • Spinal Cord Injury - Therapeutics under Development by Companies
  • Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes
  • Spinal Cord Injury - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Spinal Cord Injury - Products under Development by Companies
  • Spinal Cord Injury - Products under Investigation by Universities/Institutes
  • Spinal Cord Injury - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Acorda Therapeutics Inc
    • Asterias Biotherapeutics, Inc.
    • Asubio Pharma Co Ltd
    • Athersys Inc
    • BioArctic Neuroscience AB
    • BioAxone BioSciences Inc
    • Genervon Biopharmaceuticals LLC
    • Histocell SL
    • Kadimastem Ltd
    • Kringle Pharma Inc
    • Lpath Inc
    • MandalMed Inc
    • Mapreg SAS
    • Medgenics Inc
    • Neuralstem Inc
    • Neuronax SAS
    • New World Laboratories Inc
    • Omeros Corp
    • PharmatrophiX, Inc.
    • Pharmicell Co Ltd
    • Protagenic Therapeutics Inc.
    • Q Therapeutics Inc
    • Remedy Pharmaceuticals Inc
    • RespireRx Pharmaceuticals Inc
    • SanBio Inc
    • Stemedica Cell Technologies Inc
    • TissueGene Inc
    • TRB Chemedica International SA
    • Tumorend LLC
    • Vertex Pharmaceuticals Inc
    • Vicore Pharma AB
  • Spinal Cord Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (buspirone + carbidopa + levodopa) - Drug Profile
    • ABT-555 - Drug Profile
    • AP-325 - Drug Profile
    • APO-1 - Drug Profile
    • ASTOPC-1 - Drug Profile
    • AX-007 - Drug Profile
    • BA-277 - Drug Profile
    • BA-434 - Drug Profile
    • C-21 - Drug Profile
    • Cell Therapy for Spinal Cord Injury - Drug Profile
    • Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile
    • Cellgram-SCI - Drug Profile
    • CHEC-7 - Drug Profile
    • CHEC-9 - Drug Profile
    • chondroitinase ABC nanosphere - Drug Profile
    • CLR-01 - Drug Profile
    • CM-101 - Drug Profile
    • CX-717 - Drug Profile
    • Drug for Spinal Cord Injury - Drug Profile
    • FAB-117HC - Drug Profile
    • Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile
    • glyburide - Drug Profile
    • GM-603 - Drug Profile
    • HBN-1 - Drug Profile
    • ICCN-100 - Drug Profile
    • IMS-001 - Drug Profile
    • IMS-002 - Drug Profile
    • JM-4 - Drug Profile
    • KP-100IT - Drug Profile
    • LM11A-31BHS - Drug Profile
    • LPA-181 - Drug Profile
    • Lpathomab - Drug Profile
    • MAP-4343 - Drug Profile
    • Neu-2000 - Drug Profile
    • NeuroRelease SCI - Drug Profile
    • neurovitas - Drug Profile
    • NOVO-117 - Drug Profile
    • NSI-566 - Drug Profile
    • NWL-53 - Drug Profile
    • NX-210 - Drug Profile
    • Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile
    • PF-05285401 - Drug Profile
    • porcine GM1 ganglioside - Drug Profile
    • PT-00114 - Drug Profile
    • Q-Cells - Drug Profile
    • Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile
    • Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury - Drug Profile
    • SB-618 - Drug Profile
    • SB-623 - Drug Profile
    • SC-0806 - Drug Profile
    • Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile
    • Small Molecules for Spinal Cord Injury - Drug Profile
    • Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis - Drug Profile
    • Stem Cell Therapy for Central Nervous System Disorders - Drug Profile
    • Stem Cell Therapy for CNS Disorders - Drug Profile
    • Stem Cell Therapy for Neurodegenerative Diseases - Drug Profile
    • Stem Cell Therapy for Spinal Cord Injury - Drug Profile
    • Stem Cell Therapy for Spinal Cord Injury - Drug Profile
    • Stem Cell Therapy for Spinal Cord Injury - Drug Profile
    • SUN-13837 - Drug Profile
    • Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile
    • Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile
    • TG-N - Drug Profile
    • UH-0113 - Drug Profile
    • UH-0213 - Drug Profile
    • VX-210 - Drug Profile
  • Spinal Cord Injury - Dormant Projects
  • Spinal Cord Injury - Discontinued Products
  • Spinal Cord Injury - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Spinal Cord Injury, H2 2016
  • Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Spinal Cord Injury - Pipeline by AbbVie Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Acorda Therapeutics Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Asterias Biotherapeutics, Inc., H2 2016
  • Spinal Cord Injury - Pipeline by Asubio Pharma Co Ltd, H2 2016
  • Spinal Cord Injury - Pipeline by Athersys Inc, H2 2016
  • Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H2 2016
  • Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016
  • Spinal Cord Injury - Pipeline by Histocell SL, H2 2016
  • Spinal Cord Injury - Pipeline by Kadimastem Ltd, H2 2016
  • Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Lpath Inc, H2 2016
  • Spinal Cord Injury - Pipeline by MandalMed Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Mapreg SAS, H2 2016
  • Spinal Cord Injury - Pipeline by Medgenics Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Neuralstem Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2016
  • Spinal Cord Injury - Pipeline by New World Laboratories Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Omeros Corp, H2 2016
  • Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H2 2016
  • Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H2 2016
  • Spinal Cord Injury - Pipeline by Protagenic Therapeutics Inc., H2 2016
  • Spinal Cord Injury - Pipeline by Q Therapeutics Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals Inc, H2 2016
  • Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H2 2016
  • Spinal Cord Injury - Pipeline by SanBio Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2016
  • Spinal Cord Injury - Pipeline by TissueGene Inc, H2 2016
  • Spinal Cord Injury - Pipeline by TRB Chemedica International SA, H2 2016
  • Spinal Cord Injury - Pipeline by Tumorend LLC, H2 2016
  • Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Inc, H2 2016
  • Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Spinal Cord Injury - Dormant Projects, H2 2016
  • Spinal Cord Injury - Dormant Projects (Contd..1), H2 2016
  • Spinal Cord Injury - Dormant Projects (Contd..2), H2 2016
  • Spinal Cord Injury - Dormant Projects (Contd..3), H2 2016
  • Spinal Cord Injury - Dormant Projects (Contd..4), H2 2016
  • Spinal Cord Injury - Dormant Projects (Contd..5), H2 2016
  • Spinal Cord Injury - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Spinal Cord Injury, H2 2016
  • Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top